<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01606475</url>
  </required_header>
  <id_info>
    <org_study_id>1108M03061</org_study_id>
    <nct_id>NCT01606475</nct_id>
  </id_info>
  <brief_title>Islet Transplant for Type 1 or Surgical Diabetes</brief_title>
  <acronym>EXAX</acronym>
  <official_title>Human Alloislet Transplant for Type 1 or Surgical Diabetes Mellitus With Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of islet transplants from&#xD;
      human cadaver donors into type 1 or surgical diabetes mellitus patients who experience&#xD;
      frequent acute or advanced chronic complications but do not qualify for other islet&#xD;
      transplant trials. Under this protocol, patients may receive intraportal alloislet transplant&#xD;
      under one of the following scenarios:&#xD;
&#xD;
        1. islet transplant alone&#xD;
&#xD;
        2. simultaneous islet-kidney transplant, or 3)islet after kidney transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall objective of this study is to evaluate the efficacy of islet allotransplants for&#xD;
      labile diabetes mellitus in patients who do not meet standard inclusion/exclusion criteria&#xD;
      for any other islet transplant trials in the US and are not good candidates for a pancreas&#xD;
      transplant. We expect that this will include patients who have surgical diabetes (total&#xD;
      pancreatectomy) rather than type 1 diabetes, patients who are highly sensitized (PRA&gt;20%),&#xD;
      and patients who have had prior failed pancreas transplantation. These patients may have&#xD;
      equally severe hypoglycemia, glucose lability, and/or severe microvascular complications, but&#xD;
      are excluded from standard islet transplant trials currently available in the U.S.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Hypoglycemia</condition>
  <condition>Labile Diabetes</condition>
  <condition>End-stage Renal Disease</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic islets of Langerhans</intervention_name>
    <description>Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.</description>
    <other_name>Islets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients age 18 to 70 years of age.&#xD;
&#xD;
          2. Ability to provide written informed consent.&#xD;
&#xD;
          3. Mentally stable and able to comply with the procedures of the study protocol.&#xD;
&#xD;
          4. Insulin-dependent diabetes mellitus&#xD;
&#xD;
          5. Not otherwise eligible for an existing alloislet transplant protocol for type 1&#xD;
             diabetes mellitus&#xD;
&#xD;
          6. Involvement in intensive diabetes management, defined by at least 3 injections daily&#xD;
             or insulin pump therapy.&#xD;
&#xD;
          7. Meets at least one of the following criteria despite intensive efforts made in close&#xD;
             cooperation with their diabetic care team:&#xD;
&#xD;
               -  Significant hypoglycemia unawareness or glycemic lability on conventional insulin&#xD;
                  therapy, as evidenced by at least one of the following at screening:&#xD;
&#xD;
               -  Clarke score &gt; 4&#xD;
&#xD;
               -  HYPO score &gt;90th percentile (1047)&#xD;
&#xD;
               -  Lability index (LI) &gt;90th percentile (433 mM2/h/wk)&#xD;
&#xD;
               -  A composite of a Clarke score of 4 or more and a HYPO score greater than or equal&#xD;
                  to the 75th percentile (423) and a LI greater than of equal to the 75th&#xD;
                  percentile (329)&#xD;
&#xD;
               -  Progressive secondary complications as defined by end-stage renal disease&#xD;
                  necessitating dialysis or renal transplantation (eligible for islet after kidney&#xD;
                  or simultaneous islet kidney transplant) AND islet transplant appears to provide&#xD;
                  a more satisfactory benefit to risk ratio compared to pancreas transplantation&#xD;
                  (eg high surgical risk)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. HbA1c &gt;10%.&#xD;
&#xD;
          2. Untreated proliferative diabetic retinopathy.&#xD;
&#xD;
          3. Uncontrolled Hypertension (SBP&gt;160 or DBP&gt;100)&#xD;
&#xD;
          4. For female participants: Positive pregnancy test, presently breast-feeding, or&#xD;
             unwillingness to use effective contraceptive measures for the duration of the study.&#xD;
&#xD;
          5. Active infection including hepatitis B, hepatitis C, HIV, or TB as determined by a&#xD;
             positive skin test or clinical presentation, or under treatment for suspected TB.&#xD;
&#xD;
          6. Any history of malignancy except for completely resected squamous or basal cell&#xD;
             carcinoma of the skin.&#xD;
&#xD;
          7. Receiving treatment for a medical condition requiring chronic use of systemic&#xD;
             steroids, except for use of prednisone &lt;5 mg per day for kidney transplant recipients&#xD;
             or physiologic hydrocortisone replacement.&#xD;
&#xD;
          8. Persistent elevation of liver function tests at the time of study entry. Persistent&#xD;
             SGOT (AST), SGPT (ALT), Alk Phos or total bilirubin, with values &gt;1.5 times normal&#xD;
             upper limits will exclude a patient.&#xD;
&#xD;
          9. Severe co-existing cardiac disease, characterized by any one of these conditions:&#xD;
&#xD;
               -  recent myocardial infarction (within past 6 months).&#xD;
&#xD;
               -  evidence of ischemia on functional cardiac exam within the last year.&#xD;
&#xD;
               -  left ventricular ejection fraction &lt;30%.&#xD;
&#xD;
         10. If diabetes is secondary to total pancreatectomy, participants will be considered only&#xD;
             if &gt;1 year out from surgery, medically stable, without severe issues with bowel&#xD;
             function or pain management that may interfere with safe completion of the trial.&#xD;
&#xD;
         11. History of alcoholism&#xD;
&#xD;
         12. Any medical condition that, in the opinion of the investigator, will interfere with&#xD;
             the safe completion of the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Bernhard J Hering, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melena Bellin, MD</last_name>
    <phone>612-625-4686</phone>
    <email>bell0130@umn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Alisha Albrecht</last_name>
      <phone>612-624-8402</phone>
      <email>albre441@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Bernhard J Hering, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melena Bellin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 23, 2012</study_first_submitted>
  <study_first_submitted_qc>May 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2012</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Islet transplant</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

